Immunotherapies: Partnership models driving cures

November 24, 2016 Christoph Graener

While we have seen new immunotherapies enter the market and there are many exciting products in development; we have also seen recent setbacks. The field is risky and partnerships among biotechs, pharmas, and other stakeholders are critical in bringing the next generation of treatments to fruition. How can companies work together to minimize the risk, maximize the potential, and ultimately help patients?

Moderator: Jeffrey M. Bockman – Defined Health

  • Paul Biondi – Bristol-Myers Squibb
  • Niels P. Emmerich – AbbVie
  • Bernd Muehlenweg – Nanobiotix
  • Stefanos Theoharis – Cell Medica
  • Pierre Vandepapelière – Imcyse

Previous Article
The new frontier: Aging and health

As older populations become the norm in many countries, healthy aging involves proactive prevention and tre...

Next Article
Big pharma’s approach to digital medicine

Panelists share their perspectives on how therapeutic applications, clinical trials, drug delivery, and adh...